BioNTech is Biotechnology in Germany that focus on oncology pipeline business. Founded in 2008. They cover business area such as cancer therapeutic, individualized immunotherapy, vaccine, infectious disease, several class, drug, antigen, cytokine, cell therapy, bispecific antibody, small-molecule immunomodulator, several large pharmaceutical company, Roche, Eli Lilly, Pfizer, Sanofi, Genmab, Comirnaty, its first commercialize product.
2008
( 16 years old in 2024 )
Oncology Pipeline
-
An der Goldgrube 12
55131 Mainz
Germany
Private
cancer therapeuticindividualized immunotherapyvaccineinfectious diseaseseveral classdrugantigencytokinecell therapybispecific antibodysmall-molecule immunomodulatorseveral large pharmaceutical companyRocheEli LillyPfizerSanofiGenmabComirnatyits first commercialize product
* We use standard office opening hours in near BioNTech's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
BioNTech is Biotechnology business from Germany that founded in 2008 (16 years old in 2024), BioNTech business is focusing on Oncology Pipeline.
BioNTech headquarter office and corporate office address is located in An der Goldgrube 12 55131 Mainz Germany.
BioNTech was founded in Germany.
In 2024, BioNTech is currently focus on oncology pipeline sector.
Above is snippet of Google Trends for "oncology pipeline" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with BioNTech, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
